Population pharmacokinetic modeling and deconvolution of enantioselective absorption of eflornithine in the rat

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 40, Issue 1, 2013, Pages 117-128

  Johansson, Carl Christer ^a   Gennemark, Peter ^b   Artursson, Per ^c   Äbelö, Angela ^a   Ashton, Michael ^a   Jansson Löfmark, Rasmus ^a,b  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

Deconvolution; Eflornithine; NONMEM; Pharmacokinetics; Rat

Indexed keywords

EFLORNITHINE;

ANALYTIC METHOD; ANIMAL EXPERIMENT; ARTERIAL BLOOD SAMPLING KIT; ARTICLE; CELL STRAIN CACO 2; DECONVOLUTION METHOD; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG PENETRATION; ENANTIOSELECTIVITY; MALE; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; STEREOCHEMISTRY;

ABSORPTION; ANIMALS; BIOLOGICAL AVAILABILITY; CACO-2 CELLS; CELL LINE, TUMOR; EFLORNITHINE; ENZYME INHIBITORS; HUMANS; MALE; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; RATS; RATS, SPRAGUE-DAWLEY; STEREOISOMERISM;

EID: 84872912221     PISSN: 1567567X     EISSN: 15738744     Source Type: Journal    
DOI: 10.1007/s10928-012-9293-x     Document Type: Article

References (42)

1. Qu N, Ignatenko NA, Yamauchi P, Stringer DE, Levenson C, Shannon P, Perrin S, Gerner EW (2003) Inhibition of human ornithine decarboxylase activity by enantiomers of difluoromethylornithine. Biochem J 375(Pt 2):465-470
2. Bacchi CJ, Nathan HC, Hutner SH, McCann PP, Sjoerdsma A (1980) Polyamine metabolism: a potential therapeutic target in trypanosomes. Science 210(4467):332-334
3. Raul F (2007) Revival of 2-(difluoromethyl)ornithine (DFMO), an inhibitor of polyamine biosynthesis, as a cancer chemopreventive agent. Biochem Soc Trans 35(Pt 2):353-355
4. Ignatenko NA, Besselsen DG, Stringer DE, Blohm-Mangone KA, Cui H, Gerner EW (2008) Combination chemoprevention of intestinal carcinogenesis in a murine model of familial adenomatous polyposis. Nutr Cancer 60(Suppl 1):30-35
5. Gerner EW, Meyskens FL Jr, Goldschmid S, Lance P, Pelot D (2007) Rationale for, and design of, a clinical trial targeting polyamine metabolism for colon cancer chemoprevention. Amino Acids 33(2):189-195
6. McLaren CE, Fujikawa-Brooks S, Chen WP, Gillen DL, Pelot D, Gerner EW, Meyskens FL Jr (2008) Longitudinal assessment of air conduction audiograms in a phase III clinical trial of difluoromethylornithine and sulindac for prevention of sporadic colorectal adenomas. Cancer Prev Res (Phila Pa) 1(7):514-521
7. Mackenzie GG, Ouyang N, Xie G, Vrankova K, Huang L, Sun Y, Komninou D, Kopelovich L, Rigas B (2011) Phospho-sulindac (OXT-328) combined with difluoromethylornithine prevents colon cancer in mice. Cancer Prev Res (Phila) 4(7):1052-1060
8. Kennedy PG (2004) Human African trypanosomiasis of the CNS: current issues and challenges. J Clin Invest 113(4):496-504
9. Kennedy PG (2008) The continuing problem of human African trypanosomiasis (sleeping sickness). Ann Neurol 64(2):116-126
10. Jacobs RT, Nare B, Phillips MA (2011) State of the art in African trypanosome drug discovery. Curr Top Med Chem 11(10):1255-1274
11. Docampo R, Moreno SN (2003) Current chemotherapy of human African trypanosomiasis. Parasitol Res 90(Supp 1):S10-S13
12. Balasegaram M, Young H, Chappuis F, Priotto G, Raguenaud ME, Checchi F (2008) Effectiveness of melarsoprol and eflornithine as first-line regimens for gambiense sleeping sickness in nine Medecins Sans Frontieres programmes. Trans R Soc Trop Med Hyg 103(3):280-290
13. Priotto G, Kasparian S, Mutombo W, Ngouama D, Ghorashian S, Arnold U, Ghabri S, Baudin E, Buard V, Kazadi-Kyanza S, Ilunga M, Mutangala W, Pohlig G, Schmid C, Karunakara U, Torreele E, Kande V (2009) Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial. Lancet 374(9683):56-64
14. Burri C (2010) Chemotherapy against human African trypanosomiasis: is there a road to success? Parasitology 137(14):1987-1994
15. Na-Bangchang K, Doua F, Konsil J, Hanpitakpong W, Kamanikom B, Kuzoe F (2004) The pharmacokinetics of eflornithine (alpha-difluoromethylornithine) in patients with late-stage T.b. gambiense sleeping sickness. Eur J Clin Pharmacol 60(4):269-278
16. Sanderson L, Dogruel M, Rodgers J, Bradley B, Thomas SA (2008) The blood-brain barrier significantly limits eflornithine entry into Trypanosoma brucei brucei infected mouse brain. J Neurochem 107(4):1136-1146
17. Haegele KD, Alken RG, Grove J, Schechter PJ, Koch-Weser J (1981) Kinetics of alpha-difluoromethylornithine: an irreversible inhibitor of ornithine decarboxylase. Clin Pharmacol Ther 30(2):210-217
18. Burri C, Brun R (2003) Eflornithine for the treatment of human African trypanosomiasis. Parasitol Res 90(Supp 1):S49-S52
19. Jansson R, Malm M, Roth C, Ashton M (2008) Enantioselective and nonlinear intestinal absorption of eflornithine in the rat. Antimicrob Agents Chemother 52(8):2842-2848
20. Malm M, Bergqvist Y (2007) Determination of eflornithine enantiomers in plasma, by solid-phase extraction and liquid chromatography with evaporative light-scattering detection. J Chromatogr B Analyt Technol Biomed Life Sci 846(1-2):98-104
21. Jansson-Lofmark R, Romsing S, Albers E, Ashton M (2010) Determination of eflornithine enantiomers in plasma by precolumn derivatization with o-phthalaldehyde-N-acetyl-l-cysteine and liquid chromatography with UV detection. Biomed Chromatogr 24(7):768-773
22. Hubatsch I, Ragnarsson EG, Artursson P (2007) Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers. Nat Protoc 2(9):2111-2119
23. Beal S (1986-2006) NONMEM users guide. In: Boeckmann A ICON Development Solutions, Ellicot City
24. Madden FN, Godfrey KR, Chappell MJ, Hovorka R, Bates RA (1996) A comparison of six deconvolution techniques. J Pharmacokinet Biopharm 24(3):283-299
25. Jonsson EN, Karlsson MO (1999) Xpose - an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 58(1):51-64
26. Lindbom L, Pihlgren P, Jonsson EN (2005) PsN-Toolkit - a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed 79(3):241-257
27. Karlsson MO, Molnar V, Freijs A, Nygren P, Bergh J, Larsson R (1999) Pharmacokinetic models for the saturable distribution of paclitaxel. Drug Metab Dispos 27(10):1220-1223
28. Mager DE, Jusko WJ (2001) General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn 28(6):507-532
29. Verotta D (1996) Concepts, properties, and applications of linear systems to describe distribution, identify input, and control endogenous substances and drugs in biological systems. Crit Rev Biomed Eng 24(2-3):73-139
30. de Boor C (2001) Smoothing and least-squares approximation. In: Applied mathematical sciences 27 - a practical guide to splines. Springer, New York, pp 211-214
31. Barrett MP, Boykin DW, Brun R, Tidwell RR (2007) Human African trypanosomiasis: pharmacological re-engagement with a neglected disease. Br J Pharmacol 152(8):1155-1171
32. Seely JE, Poso H, Pegg AE (1982) Measurement of the number of ornithine decarboxylase molecules in rat and mouse tissues under various physiological conditions by binding of radiolabelled alpha-difluoromethylornithine. Biochem J 206(2):311-318
33. Lin JH (1995) Species similarities and differences in pharmacokinetics. Drug Metab Dispos 23(10):1008-1021
34. Davies B, Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res 10(7):1093-1095
35. Grimble GK (2007) Adverse gastrointestinal effects of arginine and related amino acids. J Nutr 137(6 Suppl 2):1693S-1701S
36. Cynober L (2007) Pharmacokinetics of arginine and related amino acids. J Nutr 137(6 Suppl 2):1646S-1649S
37. Pan M, Choudry HA, Epler MJ, Meng Q, Karinch A, Lin C, Souba W (2004) Arginine transport in catabolic disease states. J Nutr 134(10 Suppl):2826S-2829S discussion 2853S
38. Matsson P, Bergstrom CA, Nagahara N, Tavelin S, Norinder U, Artursson P (2005) Exploring the role of different drug transport routes in permeability screening. J Med Chem 48(2):604-613
39. Lennernas H (2007) Intestinal permeability and its relevance for absorption and elimination. Xenobiotica 37(10-11):1015-1051
40. Linnankoski J, Makela J, Palmgren J, Mauriala T, Vedin C, Ungell AL, Lazorova L, Artursson P, Urtti A, Yliperttula M (2010) Paracellular porosity and pore size of the human intestinal epithelium in tissue and cell culture models. J Pharm Sci 99(4):2166-2175
41. Chiba H, Osanai M, Murata M, Kojima T, Sawada N (2008) Transmembrane proteins of tight junctions. Biochim Biophys Acta 1778(3):588-600
42. Liu L, Guo X, Rao JN, Zou T, Xiao L, Yu T, Timmons JA, Turner DJ, Wang JY (2009) Polyamines regulate E-cadherin transcription through c-Myc modulating intestinal epithelial barrier function. Am J Physiol Cell Physiol 296(4):C801-C810